At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 161 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD; #2
In Brief
A Phase 2 clinical trial evaluating Flortaucipir F18 and Brain PET Scan for Alzheimer Disease. Completed, enrolled 161 participants across 9 sites.
Detailed Summary
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedMar 2018
Primary CompletionNov 2018
TodayJul 2026
First PostedMar 16, 2018
Enrollment StartMar 8, 2018
Primary CompletionNov 15, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.3 years ago
Interventions
Flortaucipir F18drug
370 megabecquerel (MBq) IV single-dose
Brain PET Scanprocedure
positron emission tomography (PET) scan of the brain